India has become China's top market for active pharmaceutical ingredients, now estimated at almost $2 billion annually, or almost 15% of its API exports, and many Chinese pharma companies are eager to expand that trade. "China should adopt the high standards of quality and also look to making strides in the generic industry here," said Shi Shengyi, speaking for the China National Pharmaceutical Group Corp., Sinopharm.

Related Summaries